Get in Touch

Schedule IIIOn April 22, 2026, the Department of Justice did something the cannabis industry had been promised for thirty years and warned about for fifteen. It rescheduled marijuana — partially. Not all of it. Not even most of it. Just the slice handled under a state medical marijuana license, plus FDA-approved products. Everything else stays in Schedule I, where it has lived since Nixon was telling Elvis what year it was.

That partial reclassification is the most important single regulatory action in cannabis since California passed Proposition 215 in 1996. Every operator, CFO, banker, payment processor, state legislator, and cannabis investor now lives in a world where federal law treats two pots of identical product completely differently based on a paper qualification. If you hold the right state license, you handle a Schedule III drug. If you do not, you handle a Schedule I drug. Same plant. Different schedule. Different tax treatment. Different banking risk. Different DEA registration obligation. Different valuation.

This hub is the complete operator, lawyer, and investor briefing on Schedule III cannabis. Sixteen cluster posts, organized by who you are and what problem you are trying to solve. We built it because every cannabis CFO, banking partner, state policy staffer, and capital markets desk in the country is trying to figure out the same thing right now and the regulatory press releases aren’t going to do it for them.

TL;DR: The DOJ April 2026 Final Order moved FDA-approved marijuana products and marijuana subject to a qualifying state-issued medical marijuana license into Schedule III. Noncovered marijuana stays in Schedule I. State-licensed medical operators get 280E relief, an expedited DEA registration pathway, materially better banking arguments, and a path toward card-network feasibility. Operators outside that lane get a much harder regulatory file. The state-policy play is the OTC Therapeutic Cannabis Endorsement model — convert every adult-use license into a state medical marijuana license through universal medical endorsement and adult self-certification. This hub explains every piece.

What changed on April 22, 2026 (the Schedule III cannabis short version)

DOJ and DEA published a Final Order that does five things, in plain English:

  1. Reschedules a slice of marijuana to Schedule III. Specifically: FDA-approved products containing marijuana, and marijuana subject to a qualifying state-issued medical marijuana license. The Final Order leaves all other marijuana — bulk, unlicensed, recreational without a medical endorsement, hemp that crosses the THC line — in Schedule I.
  2. Creates an expedited DEA registration pathway for state medical marijuana licensees. Sixty-day filing window, streamlined Subpart C requirements, federal-register publication.
  3. Adds import / export permit obligations consistent with Single Convention treaty controls.
  4. Sets a June 29, 2026 expedited hearing on broader rescheduling questions.
  5. Triggers Treasury / IRS guidance on tax consequences — including potential 280E retrospective relief for state medical licensees.

The legal authority is unusual. DOJ relied on 21 U.S.C. § 811(d)(1) — the treaty-control provision — rather than the standard § 811(a) eight-factor analysis. The legal theory: the Single Convention requires control of cannabis, but does not require Schedule I. Schedule III plus registration, permits, quotas, and records satisfies the treaty obligation while reflecting medical use. That theory is litigation bait. It will be tested. Operators who organize around the medical lane today are betting (correctly, in our view) that the channel-based architecture survives the litigation regardless.

For the day-one operator, banker, and CFO checklist, see our Cluster 1 explainer: Medical Marijuana Rescheduling: 5 Critical Things Operators Must Do Now.

Who this Schedule III cannabis hub is for

Different audiences read the same Final Order and care about different things. We built this hub with six audience entry points. Pick yours, jump to the relevant cluster, and skip the rest.

For cannabis operators

You want to know whether you qualify as a state medical licensee under the order, what 280E does for your tax bill this year, whether your bank will keep your account, whether the DEA registration window applies to you, and how to update your operating playbook before the June 29 hearing. Start here:

For CPAs, CFOs, and tax counsel

Section 280E reads “Schedule I or II.” Schedule III is neither. If your client holds a state medical marijuana license, deductions and credits previously disallowed for Schedule I or II trafficking are now potentially available. Treasury has signaled retrospective relief is on the table. The work is documentation, allocation methodology, and protective claims. Start here:

For banks, payment processors, and merchant-services counsel

FinCEN’s 2014 guidance still applies. SAR filings still apply. BSA / AML obligations still apply. What changed: state-medical-endorsed transactions can now be argued out of Schedule I, which materially improves the risk file. Card networks have not changed their rules — yet. Start here:

For state lawmakers, attorney general staff, and policy directors

Your job for the next 18 months is to decide whether your state’s licensed cannabis market lives inside the Schedule III lane or outside it. The deciding question is whether your state has converted its adult-use program into a state medical marijuana licensing system. The cleanest legislative model we’ve found is the OTC Therapeutic Cannabis Endorsement — universal medical endorsement on every license + adult self-certification + transaction-level medical records + certified consultants. Start here:

For investors, lenders, and M&A counsel

Schedule III recognition is a balance-sheet event. License status becomes the bridge between recreational-cap revenue multiples and pharma-grade revenue multiples. Risk-factor language in your S-1 / PPM / data-room memo needs rewriting. Start here:

For researchers, universities, and pharmaceutical sponsors

Schedule III drops marijuana research from Schedule I’s research-registration regime to Schedule III’s. Source-of-supply pathways open up for DEA-registered investigators. IRB and FDA IND interplay matters. Start here:

All 16 topics in the Schedule III cannabis hub

The complete cluster index. (Schema: this list powers the ItemList JSON-LD.)

  1. DOJ Final Order Explained — Medical Marijuana Rescheduling — What the April 22, 2026 Final Order actually does, what’s still Schedule I, and the 5 actions every operator should take this week.
  2. 280E Retrospective Relief for State Medical Licensees — Treasury / IRS retrospective-relief signal, protective claims, and the CPA’s allocation-methodology playbook.
  3. Cannabis Banking Under Schedule III — The state-medical-endorsement file your bank actually needs. FinCEN, BSA, SAR, and the 2014 guidance updated for the post-Order world.
  4. Credit Card Processing & Schedule III Cannabis — Why Visa and Mastercard didn’t move on April 23, what would force them to, and the merchant-onboarding file that gives you the best shot.
  5. The OTC Therapeutic Cannabis Endorsement Model Act — The federal-defensible state-legislation framework: universal medical endorsement, adult self-certification, transaction-level records, and ten-pillar architecture.
  6. Adult Self-Certification for Cannabis — How D.C. and Washington solved the medical-access problem without physician gatekeeping, and how to bake it into a Schedule III-ready program.
  7. Federal Cannabis License: DEA Registration After Schedule III — Ten critical steps for the expedited registration pathway, the 60-day filing window, and the Subpart C compliance file.
  8. State-by-State Schedule III Conversion Playbook — Adult-use plus medical, medical-only, low-THC, and prohibition states each get a different playbook. Here’s all four.
  9. Schedule III Cannabis Investor Disclosure & Risk Factors — S-1 risk-factor language, PPM updates, data-room diligence checklists, and the multiple expansion case.
  10. Medical Cannabis Consultant / Pharmacist Overlay — The Washington consultant model, telehealth integration, and how to build the federally-defensible retail lane.
  11. Cannabis Research Registration After Schedule III — DEA registration for academic researchers, source-of-supply pathways, and the IRB/IND interplay.
  12. Cannabis M&A Under Schedule III — Diligence updates, reps & warranties, and the state-medical-endorsement premium.
  13. Cannabis Valuations Under Schedule III — The 280E multiplier and what enterprise value looks like once the deduction disallowance lifts.
  14. Schedule III Cannabis 101 — The plain-English explainer for new readers, journalists, and stakeholders meeting the Final Order for the first time.
  15. How We Got to Schedule III: 2024–2026 Timeline — The historical record. CSA scheduling, OLC opinion, EO 14370, and the path through DOJ.
  16. IRC 280E After Schedule III: The Cleanup Memo — The legal mechanics of why 280E never applied to Schedule III in the first place, and what that means for state medical licensees today.

The state-medical-license channel is now the most valuable license class in the country

If you take nothing else from this hub, take this. A cannabis license has always been a state asset. As of April 22, 2026, the right kind of cannabis license is also a federal asset.

The Final Order’s covered channel — marijuana subject to a qualifying state-issued medical marijuana license — is doing four jobs at once. It is the federal predicate for Schedule III treatment. It is the federal predicate for 280E relief. It is the federal predicate for an expedited DEA registration pathway. It is the federal predicate for the strongest available banking and payment-network argument.

Every one of those federal predicates depends on whether your state license fits the description. That, in turn, depends on whether your state has done the legislative work to convert its program into a state medical marijuana licensing framework. Adult-use-only states are leaving federal value on the table. Medical-only states with narrow qualifying conditions are leaving federal value on the table. Hybrid states that maintain a separate adult-use track outside the medical endorsement are leaving federal value on the table.

The fix — for any state — is the OTC Therapeutic Cannabis Endorsement Model. Universal medical endorsement on every license. Adult self-certification 21+. Transaction-level medical-purpose records. Certified consultants or pharmacist overlay. Enhanced traditional patient tier preserved. Public-health and anti-diversion controls strengthened. We’ve drafted the model statute. State lawmakers can have it tomorrow. See Cluster 5 for the architecture.

This is the move. States that pass it first give their operators a federal-recognition advantage that translates immediately into tax, banking, payments, and valuation upside. States that wait are explaining to constituents in 2027 why every operator from a neighboring state is sitting on a 30-percent enterprise-value premium they didn’t get.

Five things this hub will not tell you

Honesty is part of the brand, so here are the things this hub will not pretend to do for you.

  1. Make cannabis federally legal. It isn’t. The Final Order rescheduled a slice. Schedule III is not legalization, and we will say it five hundred times because somebody on Twitter is already lying about it.
  2. Force Visa or Mastercard to accept your transactions. They are private networks. They write their own rules. The Schedule III argument is materially better, but it is still an argument, not a court order. See Cluster 4 for what would actually move them.
  3. Bind DEA to your state license. DEA decides registrations, not state regulators. The expedited pathway is a process improvement, not a guaranteed yes. See Cluster 7 for the registration file.
  4. Eliminate FinCEN, BSA, or SAR obligations. Banks still file SARs on cannabis. They will continue to. The 2014 FinCEN guidance is still law. What changed is the underlying file argument. See Cluster 3.
  5. Survive the inevitable litigation. DOJ used § 811(d)(1) treaty-control authority. Industry challengers, state attorneys general (in both directions), and law-and-order plaintiffs will sue. Some of those suits will succeed in part. The Final Order may be remanded, narrowed, or affirmed. The smart operator builds the file that survives any of those outcomes. See Cluster 1 for the action checklist.

The Howard Law Group / Howard East product line

We didn’t write 16 cluster posts to be helpful. We wrote 16 cluster posts because we have five legal products built specifically for the Schedule III moment, and the people who need them are searching for the questions these posts answer.

Product

Who buys it

What it includes

State OTC Therapeutic Cannabis Model Act

Governors’ policy staff, AGs, state senate cannabis committee chairs

Legislative drafting + policy memo + fiscal/tax impact + federal-defensibility analysis. White-glove.

Operator Schedule III Readiness Review

Existing licensees with $5M+ revenue

License/endorsement audit, 280E allocation, banking file build, DEA-readiness package, transition memo

Banking & Payments Compliance Packet

MRBs preparing for new banking relationships, banks underwriting MRBs

State license verification API, FinCEN due-diligence checklist, BSA/SAR risk memo, payment-network onboarding file

CPA / Tax Counsel 280E Package

CPAs and tax counsel for cannabis operators

Covered-activity analysis, retrospective-relief record review, allocation memo, protective-claim strategy

Investor / Lender Disclosure Package

Cannabis funds, lenders, public-co counsel, M&A buyers

Risk factors, Schedule III eligibility memo, litigation risk assessment, tax-normalization assumptions, compliance representations

Every cluster post in this hub ends with a CTA into one of those five products. That is not subtle. We are openly building the index that converts inbound interest into a paying engagement, because the alternative is letting MJBizDaily and Marijuana Moment have the SEO and watching the dollars walk to the firm that did the work.

If you want to skip the hub and just talk: Book a Schedule III strategy call. Tell us which audience you fall into and we’ll route you to the right product.

Schedule III cannabis FAQ

Did the DOJ April 2026 Final Order legalize marijuana federally?

No. It rescheduled FDA-approved marijuana products and marijuana subject to a qualifying state-issued medical marijuana license to Schedule III. Everything else stays in Schedule I. Schedule III still requires DEA registration, still has FDCA implications, and still leaves card-network rules untouched. It is a partial, channel-based reclassification, not legalization.

Does Schedule III mean my state-licensed dispensary no longer pays 280E?

If your dispensary qualifies as a state medical marijuana licensee under the Final Order, then the 280E disallowance — which applies only to trafficking in Schedule I or Schedule II controlled substances — should not apply to your covered activity. Treasury and IRS have signaled forthcoming guidance on retrospective relief and apportionment for mixed activity. The cleanest position is built on documented allocation. See Cluster 2 for the protective-claim playbook.

Can my dispensary now accept Visa or Mastercard?

Not automatically. Visa and Mastercard are private rule-systems. Their cannabis prohibition was historically grounded in federal illegality. Schedule III recognition gives the merchant-services file a much stronger argument, but the networks have not changed their rules as of this writing. See Cluster 4 for the merchant-onboarding file and what would force the networks to move.

Do I have to register with DEA now?

If you are a state medical marijuana licensee, the expedited DEA registration pathway is open with a 60-day filing window. The pathway streamlines Subpart C requirements for state licensees. You do not have to register tomorrow, but the security plan, recordkeeping, and federal-readiness file should be built today regardless. See Cluster 7.

My state only has adult-use cannabis. Are we cut out of Schedule III?

Functionally, yes — until your state amends its cannabis statute to bring licensed activity inside a state medical marijuana licensing framework. The cleanest fix is the OTC Therapeutic Cannabis Endorsement model: universal medical endorsement on every license + adult self-certification. It captures adult-use commerce inside the medical lane without rewriting the politics. See Cluster 5.

When does the rest of marijuana get rescheduled?

The Final Order set an expedited hearing for June 29, 2026 on broader rescheduling questions. Beyond that, there is no formal commitment in the order. Industry advocates expect further movement in late 2026 / early 2027. Litigation may delay or reshape that. See Cluster 15 for the historical timeline.

Is hemp in Schedule III now?

No. Hemp is defined separately under the 2018 Farm Bill (THC ≤0.3% by dry weight) and remains a separate federal category. The Final Order does not modify the Farm Bill or hemp’s status. Hemp banking and the new FinCEN era have their own analysis — see Hemp banking after FinCEN guidance.

Get on the right side of Schedule III

We will say this twice because it matters twice. The Schedule III moment is a balance-sheet event for licensed cannabis operators, a legislative product opportunity for state lawmakers, a diligence event for capital markets, and a once-in-a-decade brand moment for the firms that show up first with serious work product.

You are reading this on cannabisindustrylawyer.com. The lawyers behind this hub — Howard Law Group and Howard East — are taking calls this week from operators, CPAs, banks, state policy directors, capital markets, and pharma sponsors trying to figure out their Schedule III move. Book a Schedule III strategy call and we will route you to the right product.

Primary federal materials

Read the DOJ announcement, the final rule / final order, the OLC rescheduling opinion, and FinCEN marijuana-related business guidance.

Want to Talk with a Cannabis Lawyer?

Fill out the form below and we will be in touch immediately to review your case. Thanks.